Published online Sep 26, 2021. doi: 10.12998/wjcc.v9.i27.8061
Peer-review started: May 18, 2021
First decision: June 15, 2021
Revised: June 29, 2021
Accepted: August 3, 2021
Article in press: August 3, 2021
Published online: September 26, 2021
Cervical cancer is one of the most common malignant tumors in the female reproductive system, with a high incidence, second only to breast cancer. Generally, chronic cervical inflammation evolves into precancerous lesions. In recent years, the incidence of cervical cancer has increased with increasing life pressures and changes in women's social roles, posing a serious threat to women's physical and mental health. Most patients are in the middle and late stages at presentation.
This study provides guidance for clinical treatment of advanced cervical squamous cell carcinoma.
This study aimed to explore the clinical effect of Endo combined with concurrent radiotherapy and chemotherapy in the treatment of advanced cervical squamous cell carcinoma.
A total of 120 patients admitted to the oncology department of our hospital were selected as the research subjects. They were equally divided into the test group and the control group (60 patients each) with a random number table. The test group was treated with Endo combined with concurrent radiotherapy and chemotherapy, and the control group was treated with concurrent radiotherapy and chemotherapy. The serum thymidine kinase 1 (TK1), human epididymis protein 4 (HE4), vascular endothelial growth factor (VEGF), and squamous cell carcinoma-associated antigen (SCC-Ag) levels, the clinical effects and survival before and after radiotherapy and chemotherapy, the quality score, and the 3-year follow-up outcomes between the two groups were compared.
After chemotherapy, the complete remission + partial remission rate was 85.00% in the test group and 68.33% in the control group; the difference was not statistically significant. Before chemotherapy, the serum TK1, HE4, VEGF, and SCC-Ag levels of the two groups were not significantly different. After chemotherapy, the levels of serum TK1, HE4, VEGF, and SCC-Ag were lower than those in the control group. The difference was statistically significant.
Endo combined with concurrent radiotherapy and chemotherapy for the treatment of advanced cervical squamous cell carcinoma has a positive effect on reducing the level of tumor markers in patients, prolonging the progression-free survival and overall survival times of patients, and improving the quality of life.
Endo combined with concurrent radiotherapy and chemotherapy has a positive effect on patients with advanced cervical squamous cell carcinoma, and has certain practical significance for clinical treatment.